MIAMI, FL / ACCESSWIRE / May 16, 2024 / Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of neurological treatments, announces the Company's continued inability to undertake certain corporate actions (name and symbol change, M&A, Reverse Split etc.) due to uncorrectable regulatory filing... Read More

The distress in the psychedelic space contributed to the Company's challenges. The inability of the Company to undertake certain corporate actions (name and symbol change etc.) due to regulatory filing deficiencies from over a decade ago has hampered the ability of the Company to reposition itself. MIAMI, FL / ACCESSWIRE / January 17, 2024 / Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC PINK:BWVI),... Read More

MIAMI, FL / ACCESSWIRE / December 12, 2023 / Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of treatments for neurological diseases, is thrilled to announce the appointment of Dr. Neilank K. Jha as its new Executive Chairman and Chief Executive Officer. Dr. Jha is recognized for his extensive... Read More

Investors are invited to support Psycheceutical's mission to revolutionize psychedelic medicines by taking part in the company's Wefunder Community Round. Community Crowdfunding Campaign now live for all levels of investors " Original Shark" Kevin Harrington, from the hit TV show Shark Tank , joined as an investor and strategic advisor Psycheceutical's NeuroDirect™ ketamine technology is the first ketamine topical being... Read More

Company's novel NeuroDirect TM topical ketamine formulation to treat PTSD shown to be safe and well-tolerated in first cohort of Phase I trial. MIAMI, FL / ACCESSWIRE / August 10, 2023 / Psycheceutical Bioscience, Inc . ("Psycheceutical" or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, today announced the completion... Read More

Multi-year PCAOB audited financials completed Company on the path to become fully SEC reporting Future corporate action with name and symbol change MIAMI, FL / ACCESSWIRE / August 1, 2023 / Psycheceutical Bioscience, Inc. ("Psycheceutical'' or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, today announced that its... Read More

Psycheceutical's clinical trial program is the first ever to test the topical application of ketamine for use in treating a mental health disorder through the company's NeuroDirect™ delivery system. MIAMI, FL / ACCESSWIRE / July 13, 2023 / Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental... Read More

As Psycheceutical prepares to begin clinical trials for its novel NeuroDirect ™ ketamine topical to treat PTSD, the company is named to Life Science Review's yearly Top Biotech Start-Up List MIAMI , April 13, 2023 /PRNewswire/ -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health... Read More

Psycheceutical Chief Visionary Officer Zappy Zapolin and CEO Chad Harman with MAPS Founder Rick Doblin MIAMI, March 29, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of... Read More

A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of applying NeuroDirect™ ketamine topical cream Patients indicated their thought processes were clearer and more focused, and were more keenly aware of surroundings MIAMI, March 21, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC:... Read More

When the average person thinks about psychedelics, it is easy to conjure up a picture of a trippy experience with hallucinogenic visions, and ‘Lucy In The Sky With Diamonds’ playing in the background. And if you aren’t familiar with the nuanced discussions that have recently arisen around the use of psychedelics for mental health treatment, you’d be right. Psychedelics are psychoactive substances that change mood, perception... Read More

Psycheceutical ​​enters into agreement with iNGENū to conduct ​human ​clinical trials of NeuroDirect™ ketamine topical ​in Australia Phase I trial will study 20 people to test the safety, tolerability, and pharmacokinetics of a single dose of NeuroDirect™ ketamine Phase II trial will study 115 participants with PTSD and look at the effectiveness of NeuroDirect™ ketamine on improving their symptoms MIAMI, Feb. 15, 2023 (GLOBE... Read More

MIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge brain delivery technologies for the next generation of mental health treatments, is pleased to announce it has completed its pre-Investigational New Drug ("IND") meeting with the U.S. Food and Drug Administration (FDA) and received positive... Read More

Topical ketamine formulations could improve the methods of treating post-traumatic stress disorder (PTSD) MIAMI, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge treatments for mental health, has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for the... Read More